Vaccinations with Live-attenuated Leishmania Major Promastigotes and Challenge Infection with L. Major in BALB/c Mice.
| dc.contributor.author | Onyalo, Janet Achieng' | |
| dc.contributor.author | Mwala, D. M. | |
| dc.contributor.author | Anjili, C. O. | |
| dc.contributor.author | Orago, A. S. | |
| dc.contributor.author | Tonui, W. K. | |
| dc.date.accessioned | 2014-01-16T12:34:52Z | |
| dc.date.available | 2014-01-16T12:34:52Z | |
| dc.date.issued | 2005-04 | |
| dc.description.abstract | BACKGROUND: Currently there is no vaccine available in use against any form of leishmaniases worldwide. OBJECTIVE: To assess potential of a live-attenuated Leishmania major promastigates, for protection against a challenge infection with L. major in BALB/c mice. DESIGN: A laboratory based study. SETTING: Study was carried out at Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi. RESULTS: The greatest protection against challenge with L. major was seen in mice immunised with live parasites (P < 0.001) compared to vaccinations with heat killed or soluble antigens. In general, immunised mice produced high level of antileishmanial antibodies and T cell stimulation to their respective antigens. CONCLUSIONS: Our live-attenuated parasites produced by serial sub-culture of L. major parasites 118 times showed the capacity to induce appropriate cell-mediated immune responses and protection against L. major infection in BALB/c mice. Data also suggests that these parasites do not revert to virulence when injected subcutaneously in mice. | en_US |
| dc.identifier.citation | East Afr Med J. 2005 Apr;82(4):193-7. | en_US |
| dc.identifier.uri | http://ir-library.ku.ac.ke/handle/123456789/8616 | |
| dc.language.iso | en | en_US |
| dc.publisher | East African medical journal | en_US |
| dc.title | Vaccinations with Live-attenuated Leishmania Major Promastigotes and Challenge Infection with L. Major in BALB/c Mice. | en_US |
| dc.type | Article | en_US |